Arjan Diepstra
dr.
As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.
Latest publications
(215)
Activities
(38)
Press/Media
(6)
Prizes
(4)
Datasets
(1)
Supervised work
(11)
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Published in: CANCER TREATMENT REVIEWS
Access to document
10.1016/j.ctrv.2019.101931
document
Hodgkin lymphoma is a B cell derived malignancy characterized by a low number of tumor cells within an environment consisting of inflammatory cells. Recently, immune checkpoint blockade targeting the PD-1-PD-L1 axis has shown to be a great success in relapsed and refractory Hodgkin lymphoma patients. However, complete responses are scarce and median progression-free survival is limited to around 11-15 months. Efficiency of PD-1 blockade in HL might be dependent on CD4 + T cells, but also tumor associated macrophages (TAMs) and NK cells are implicated. The aim of...
Tumour necrosis as assessed with F-18-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements
Published in: European Radiology
Access to document
10.1007/s00330-019-06178-9
document
OBJECTIVES: MYC gene rearrangements in diffuse large B cell lymphomas (DLBCLs) result in high proliferation rates and are associated with a poor prognosis. Strong proliferation is associated with high metabolic demand and tumour necrosis. The aim of this study was to investigate differences in the presence of necrosis and semiquantitative 18F-FDG PET metrics between DLBCL cases with or without a MYC rearrangement. The prognostic impact of necrosis and semiquantitative 18F-FDG PET parameters was investigated in an explorative survival analysis. METHODS: Fluorescence in situ hybridisation analysis for MYC rearrangements,...
Xaver U Kahle, Menno Hovingh, Walter Noordzij, Annika Seitz, Arjan Diepstra, Lydia Visser, Anke van den Berg, Tom van Meerten, Gerwin Huls, Ronald Boellaard, Thomas C Kwee, Marcel Nijland
Complement activation and long-term graft function in ABO-incompatible kidney transplantation
Published in: World journal of nephrology
Access to document
10.5527/wjn.v8.i6.95
document
BACKGROUND: ABO-incompatible and ABO-compatible kidney transplantation are equivalent in terms of short-term graft and patient survival. This is thought to be the result of ABO-incompatible graft accommodation, which occurs when anti-blood group antibodies re-occur after transplantation but somehow do not yield their detrimental effect. The underlying mechanism is unclear, but one of the hypotheses is that this is the result of complement inhibition. Since virtually all ABO-incompatible graft biopsies are C4d positive, this complement inhibition must occur somewhere in the complement cascade after the formation of C4d has...
Marit S van Sandwijk, Astrid Klooster, Ineke Jm Ten Berge, Arjan Diepstra, Sandrine Florquin, Joris J Hoelbeek, Frederike J Bemelman, Jan-Stephan Sanders
CD27(+)CD38(hi) B Cell Frequency During Remission Predicts Relapsing Disease in Granulomatosis With Polyangiitis Patients
Published in: Frontiers in Immunology
Access to document
10.3389/fimmu.2019.02221
document
Background: Granulomatosis with polyangiitis (GPA) patients are prone to disease relapses. We aimed to determine whether GPA patients at risk for relapse can be identified by differences in B cell subset frequencies. Methods: Eighty-five GPA patients were monitored for a median period of 3.1 years (range: 0.1-6.3). Circulating B cell subset frequencies were analyzed by flow cytometry determining the expression of CD19, CD38, and CD27. B cell subset frequencies at the time of inclusion of future-relapsing (F-R) and non-relapsing (N-R) patients were compared and related to relapse-free survival....
Anouk von Borstel, Judith Land, Wayel H Abdulahad, Abraham Rutgers, Coen A Stegeman, Arjan Diepstra, Peter Heeringa, Jan Stephan Sanders